A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Sponsor: Southwest Oncology Group
Enrolling: Male and Female Patients
IRB Number: AAAR9806
U.S. Govt. ID: NCT03499808
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test for any good and bad effects of the study drug called isatuximab. Isatuximab may or may not improve your AL amyloidosis, but it could also cause side effects. Isatuximab is not approved by the Food and Drug Administration (FDA). Isatuximab has been shown to have good effects in some patients with recurring multiple myeloma. For this reason, the researchers think that isatuximab may also help patients whose amyloidosis has recurred or gotten worse. To decide if the study treatment is better than the usual approach, the study doctors will be looking to see if the study treatment increases the number of patients whose cancer responds to treatment by at least 30 percent.
This study is closed
Suzanne Lentzsch, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have AL Amyloidosis? Yes No
Have you had at least one prior therapy such as transplant, radiation, or chemotherapy? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator